Benign Prostatic Hyperplasia (BPH)
This non-infectious, non-malignant enlargement of the prostate gland occurs in 50 to 60% of men, ages 40 to 59. An increase in prostatic concentrations of potent androgen, a derivative of testosterone, is most likely the cause. Other hormone levels are also elevated, including prolactin, oestradiol, and follicle-stimulating hormone.
The enlargement of the prostate may lead to urethra obstruction. Symptoms of BPH include bladder outlet obstruction (hesitancy, increased urinary frequency, waking at night to urinate, etc.); and an enlarged, non-tender prostate gland.
Panax Ginseng (4)
Saw Palmetto (6)
Evening Primrose Oil (2)
Flax Seed Oil (2)
Glutamic Acid (1)
1. Damrau F. Benign prostatic hypertrophy: amino acid therapy for symptomatic relief. J Am Geriatr Soc 1962;10:426-30.
2. Hart JP and Cooper WL. Vitamin F in the treatment of Prostatic Hyperplasia. Lee Foundation for Nutritional Research, Report #1. Milwaukee, Wisconsin:1941.
3. Fahim M, Fahim Z, and Harman J. Zinc treatment for the reduction of hyperplasia of the prostate. Fed Proc 1976; 35:361.
4. Saito Y. Diagnosis and treatment of chronic prostatitis with special reference to experience with Cernilton. Clin Exp Med 1967; 44:387-93.
5. ESCOP monographs. Fascicule 2: Urticae radix. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997: 4.
6. Carraro J, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29(4): 231-240, 1996.
Print this page